A clinical study on microwave ablation of T1N0M0 papillary thyroid carcinoma locating in dangerous region.

IF 3.4 2区 医学 Q2 ONCOLOGY BMC Cancer Pub Date : 2025-02-11 DOI:10.1186/s12885-025-13629-8
Hui-di Zhou, Ying Wei, Zhen-Long Zhao, Lili Peng, Yan Li, Ming-An Yu
{"title":"A clinical study on microwave ablation of T1N0M0 papillary thyroid carcinoma locating in dangerous region.","authors":"Hui-di Zhou, Ying Wei, Zhen-Long Zhao, Lili Peng, Yan Li, Ming-An Yu","doi":"10.1186/s12885-025-13629-8","DOIUrl":null,"url":null,"abstract":"<p><p>To evaluate the feasibility, safety and efficiency of the microwave ablation (MWA) of T1N0M0 papillary thyroid carcinoma (PTC) locating in dangerous region. This is a clinical retrospective study, and the data of patients who underwent thermal ablation for T1N0M0 PTC from June 2016 to March 2021 were reviewed. After ablation, the rates of technical success, as well as the changes in tumor size and volume, tumor disappearance, disease progression, and complications, were assessed. According to the tumor size, the patients were divided into T1a and T1b subgroups. There was a total of 94 cases enrolled in the present study. The mean age was 43.06 ± 11.51 years (22-65 years). The median follow-up time was 33 months (25-75% IQR 24-44; 12-85months). The technical success rate was 100%. Due to expanding ablation, the MD and volume of the ablation zone increased at the 1st and 3rd months and decreased from the 12th month after ablation (p < 0.05 for all). At the end of follow-up, the complete disappearance of ablation zone occurred in 78(78/94, 82.98%) cases, including 65 (65/75, 86.67%) cases in T1a subgroup and 13(13/19, 68.4%) cases in the T1b subgroup. There was no difference between the two subgroups (p = 0.121). 5 (5/94,5.3%) patients developed disease progression, and all of them were in T1a subgroup (5/75, 6.67%). There was not significantly different between two subgroups (p = 0.559). The complication rate was 15.96% (15/94). Recurrent laryngeal nerve (RLN) injury encountered in 11 (11/75, 14.7%) cases in the T1a subgroup and 4 (4/19, 21.1%) cases in the T1b subgroup. No significant difference between the two subgroups (p = 0.74). This preliminary study indicates that MWA is an effective treatment for T1N0M0 PTC locating in dangerous region.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"240"},"PeriodicalIF":3.4000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11818028/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-13629-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

To evaluate the feasibility, safety and efficiency of the microwave ablation (MWA) of T1N0M0 papillary thyroid carcinoma (PTC) locating in dangerous region. This is a clinical retrospective study, and the data of patients who underwent thermal ablation for T1N0M0 PTC from June 2016 to March 2021 were reviewed. After ablation, the rates of technical success, as well as the changes in tumor size and volume, tumor disappearance, disease progression, and complications, were assessed. According to the tumor size, the patients were divided into T1a and T1b subgroups. There was a total of 94 cases enrolled in the present study. The mean age was 43.06 ± 11.51 years (22-65 years). The median follow-up time was 33 months (25-75% IQR 24-44; 12-85months). The technical success rate was 100%. Due to expanding ablation, the MD and volume of the ablation zone increased at the 1st and 3rd months and decreased from the 12th month after ablation (p < 0.05 for all). At the end of follow-up, the complete disappearance of ablation zone occurred in 78(78/94, 82.98%) cases, including 65 (65/75, 86.67%) cases in T1a subgroup and 13(13/19, 68.4%) cases in the T1b subgroup. There was no difference between the two subgroups (p = 0.121). 5 (5/94,5.3%) patients developed disease progression, and all of them were in T1a subgroup (5/75, 6.67%). There was not significantly different between two subgroups (p = 0.559). The complication rate was 15.96% (15/94). Recurrent laryngeal nerve (RLN) injury encountered in 11 (11/75, 14.7%) cases in the T1a subgroup and 4 (4/19, 21.1%) cases in the T1b subgroup. No significant difference between the two subgroups (p = 0.74). This preliminary study indicates that MWA is an effective treatment for T1N0M0 PTC locating in dangerous region.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
危险部位T1N0M0型甲状腺乳头状癌的微波消融临床研究。
目的探讨微波消融治疗T1N0M0甲状腺乳头状癌(PTC)危险部位的可行性、安全性和有效性。这是一项临床回顾性研究,回顾了2016年6月至2021年3月接受热消融治疗T1N0M0 PTC患者的数据。消融后,评估技术成功率、肿瘤大小和体积的变化、肿瘤消失、疾病进展和并发症。根据肿瘤大小将患者分为T1a和T1b亚组。本研究共纳入94例病例。平均年龄43.06±11.51岁(22 ~ 65岁)。中位随访时间为33个月(25-75% IQR 24-44;12 - 85个月)。技术成功率100%。由于扩大消融,消融区的MD和体积在消融后第1个月和第3个月增加,从消融后第12个月开始下降(p
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
BMC Cancer
BMC Cancer 医学-肿瘤学
CiteScore
6.00
自引率
2.60%
发文量
1204
审稿时长
6.8 months
期刊介绍: BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
期刊最新文献
Health literacy, nutrition, complementary medicine and their associations with life satisfaction in cancer patients: a cross-sectional study. Adebrelimab plus chemotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESCC): a single-center, phase II, single-arm, open-label clinical trial (ADENEO) protocol. Network pharmacology and molecular docking analysis on mechanisms of Euphorbia Lathyris L. seed in treating colorectal cancer. Clinical efficacy of HAIC combined with TACE in patients with unresectable intrahepatic cholangiocarcinoma. Integration of Ki67 and Pan-Immune-Inflammation Value (PIV) into a predictive nomogram for pathologic complete response in triple-negative breast cancer : (Ki67 and inflammation in triple-negative breast cancer).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1